Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213193Recruiting
a study about ovarian cancer surgery and bowel involvement in women like you who are taking a pill or something? actually, it's about whether to use a vaginal or something? wait, let's read the title. it's about a no-basic? wait. the title is
This study explores an alternative method to the previous approach of whether to bypass or not? or wait... it's about the use of something? wait... the title is... wait? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? you get the idea? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?until? ?title? ?title? ?title? ?title? ?title? flask? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ? what? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ? ???????????????
RomaAges 18 years+ - NCT07226856RecruitingPhase 2
New combo for advanced pancreatic cancer
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Scottsdale, ArizonaAges 18 years+ - NCT07227623Recruiting
Digital health program to help lung cancer survivors get active
This trial tests a digital health tool to help lung cancer patients improve their physical function and wellness during and after treatment. It is designed for people with early-stage lung cancer who are starting treatment with chemotherapy, immunotherapy, or radiation.
Boston, MassachusettsAges 18 years+ - NCT07229313RecruitingPhase 1
Testing KIVU-107 in advanced solid tumors
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT07232654RecruitingPhase 2
Immunotherapy plus chemoradiation for advanced cervical cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
BeijingAges 18–75 - NCT07236021Recruiting
e-Motion: emotion support for chronic cancer patients
This trial tests an online program called e-Motion that helps people with chronic cancer manage their emotions. It may help you feel more in control and better cope with your diagnosis and treatment.
Brussels, AnderlechtAges 18 years+ - NCT07237100RecruitingPhase 2
Mirdametinib for advanced NF1-mutant melanoma
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
San Francisco, CaliforniaAges 18 years+ - NCT07239466RecruitingPhase 2
Ketone supplement with radiation and chemo for rectal cancer
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
Wuhan, HubeiAges 18–75 - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07241793RecruitingPhase 2
Trastuzumab rezetecan with or without immunotherapy for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07259447Recruiting
Adaptive radiotherapy for lung cancer
This trial tests a newer, more flexible type of radiation therapy that adjusts to changes in your body during treatment. It is for people with advanced non-small-cell lung cancer who are receiving chemotherapy alongside radiation.
Leuven, Vlaams-BrabantAges Any age - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07269899RecruitingPhase 1
A study of WTX212A with or without radiation for advanced cancer
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT07291297RecruitingPhase 2
Metformin plus standard therapy for soft tissue sarcoma
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
Charlotte, North CarolinaAges 18 years+ - NCT07305727Recruiting
Can MRI scans help predict chemo-radiation success in cervical cancer?
This trial uses MRI scans taken before treatment to see if they can predict how well chemo-radiation will work for locally advanced cervical cancer. It aims to help doctors know which patients might benefit most from this therapy.
Nîmes, GardAges 18 years+ - NCT07312422RecruitingPhase 1/Phase 2
Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hangzhou, ZhejiangAges 18–75 - NCT07317505RecruitingPhase 1
Study of JMT108 for Advanced Solid Tumors
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Huntersville, North CarolinaAges 18 years+ - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07329894RecruitingPhase 1
XH001 and vaccine-activated T cells for advanced GI cancer
This trial tests a two-part treatment: an injection called XH001 plus a custom vaccine that trains your immune cells to attack tumors. It's for people with advanced stomach or bowel cancer that hasn't responded to at least two prior treatments.
BeijingAges 18–70 - NCT07330050RecruitingPhase 2
Combination treatment for advanced lung cancer after immunotherapy failure
This trial tests a combination of WAST Cell therapy and the chemotherapy drug docetaxel for people with advanced non-small cell lung cancer whose cancer progressed after treatment with a PD-1 inhibitor. The goal is to see if this combination can help shrink tumors and extend survival.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,211 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.